There is reportedly chaos at the FDA, with some outlets citing regulatory delays and staff turnover as causes for concern. The agency has an acting commissioner, and there are questions about the impact of the situation on drug development, particularly for rare diseases. Despite the turmoil, some reports suggest that FDA decisions have remained relatively steady, but the overall effect on the agency's functioning and public trust is unclear.